Fate Therapeutics (FATE) Registration filing summary

Company overview and business model

• Clinical-stage biopharma platform engineers induced pluripotent stem cells (iPSCs) into clonal master lines for scalable, off-the-shelf cellular immunotherapies.

• Pipeline includes iPSC-derived CAR T-cell and natural killer (NK) candidates; Ono collaboration covers CAR T-cell candidates for solid tumors.

• Cellular programming adds synthetic controls and multiple functional elements to produce uniform candidates intended for use alone or with standard-of-care therapies.

Financial performance and metrics

• Cash, cash equivalents and short-term investments totaled $139.1 million as of September 30, 2026.

• Prior Jefferies ATM sales generated $8.0 million gross proceeds from 2,801,602 shares in Q3 2026; that sales agreement was terminated upon entering the Leerink agreement.

Use of proceeds and capital allocation

• ATM net proceeds, if any, are intended for working capital and general corporate purposes, including R&D, clinical trials, manufacturing, G&A and capital expenditures.

• Timing and allocation depend on clinical and development progress, partnering efforts, technology advances and competition; management retains broad discretion.